# YourChoice Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yourchoice-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.yourchoicetx.com
- Total disclosed funding: $17M
- Latest round: Series A (Jul 15, 2022)
- Investors on record: 9

## About

YourChoice Therapeutics, Inc. focuses on pioneering non-hormonal male contraceptive solutions, offering innovative products that serve as effective alternatives to conventional birth control methods, thereby catering to a growing market for male reproductive health.YourChoice Therapeutics, Inc. develops non-hormonal contraceptive solutions for men. Founded in 2018 and headquartered in San Francisco, US, the company has engaged in 4 deals, with the most recent deal occurring on July 15, 2022. The company successfully raised USD 15 mn in Series A funding led by Future Ventures, with participation from Knollwood Investment Advisory, North South Ventures, Olive Tree Capital, Refactor Capital, and Rhia Ventures. The company was founded by Nadja Mannowetz, and the current CEO is Akash Bakshi.YourChoice Therapeutics specializes in creating non-hormonal, temporary male contraceptive solutions, primarily a daily pill that provides a contraceptive effect exceeding that of condoms. This product works by targeting a biological mechanism to block cell division and sperm release, allowing for a rapid return to fertility upon discontinuation. The company also explores both human and veterinary applications, having demonstrated zero sperm production in canine subjects within two weeks and significant fertility reduction in primates in a similar timeframe. Their primary market focus includes North America and Europe, where demand for male contraceptive options is rising.YourChoice Therapeutics operates a direct-to-consumer revenue model for its contraceptive pill, facilitating close engagement with end users. The business likely uses subscription services for uninterrupted monthly supply delivery, aiming to build a loyal customer base and ensure steady revenues. The pricing strategy reflects the unique benefits of their non-hormonal formulation. Collaborations with healthcare providers and specialty retailers may enhance distribution and visibility.Following the July 15, 2022 funding round, YourChoice Therapeutics plans to utilize the USD 15 mn raised in Series A to further develop its product and initiate its first clinical trial. The company is focused on designing and launching new contraceptive products while targeting expansion into additional markets, specifically aiming for increased reach in Europe and North America by 2023.

## Funding rounds

- Series A, Jul 15, 2022, $15M — Refactor Capital, Future Ventures, Rhia Ventures, Knollwood Investment Advisory, Olive Tree Capital, North South Ventures
- Seed, Apr 18, 2019 — Capitoria Ventures
- Seed, Mar 1, 2019 — Blue Bear Ventures
- Seed, Jan 1, 2019, $1.6M — Cleo Capital

## Investors

- Cleo Capital (https://capitalatlas.ai/funds/cleo-capital) — Seed
- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Seed
- Capitoria Ventures (https://capitalatlas.ai/funds/capitoria-ventures) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Series A
- Future Ventures — Series A
- Rhia Ventures (https://capitalatlas.ai/funds/rhia-ventures) — Series A
- Knollwood Investment Advisory — Series A
- Olive Tree Capital (https://capitalatlas.ai/funds/olive-tree-capital) — Series A
- North South Ventures (https://capitalatlas.ai/funds/north-south-ventures) — Series A